Tags

Type your tag names separated by a space and hit enter

Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
J Clin Endocrinol Metab. 1992 Aug; 75(2):476-83.JC

Abstract

The effects of a combined GnRH antagonist and testosterone (T) replacement regimen on gonadotropins and spermatogenesis were examined to assess its potential as a male contraceptive regimen. The potent Nal-Glu GnRH antagonist ([Ac-D2-Nal1,D4-Cl-Phe2,D3-Pal3,Arg5, D4-p-methoxybenzoyl-2-amino butyric acid6,D-Ala10]GnRH) was administered daily (7.5 mg, sc) to eight normal men for 16 weeks. T enanthate was given im starting at week 2 and every 2 weeks thereafter through week 14 of the treatment phase. Serum LH, FSH, T, and estradiol concentrations were measured frequently during the 5-week control period, the 16-week treatment phase, and the 14-week recovery phase. Semen analyses were performed every week during the control phase and every 2 weeks during the treatment and recovery phases. Seven of eight subjects became azoospermic by 6-10 weeks of treatment; the eighth subject, who failed to achieve azoospermia, suppressed his sperm count to 7 million/mL by week 14 (from a mean baseline of 42 million/mL) before treatment was prematurely terminated because of localized swelling at each of his injection sites. Sperm counts returned to baseline 10-14 weeks after the end of Nal-Glu administration. Seven of the eight subjects showed suppression of LH to the limit of assay detection (less than 0.2 U/L), whereas the eighth subject showed incomplete suppression. Serum bioactive and immunoreactive LH concentrations showed concordant responses. Mean serum FSH concentrations were also markedly suppressed. Serum T and estradiol concentrations declined dramatically during the first 2 weeks of Nal-Glu GnRH treatment, but returned to the normal physiological range after T enanthate replacement was initiated. Libido and sexual potency were maintained. No systemic side-effects, other than erythema and induration at injection sites, were observed. These data demonstrate that combined GnRH antagonist plus T treatment can predictably and reversibly induce azoospermia in most men and has potential as a male contraceptive regimen.

Authors+Show Affiliations

Division of Endocrinology Harbor-University of California-Los Angeles Medical Center, Torrance 90509.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

1639948

Citation

Tom, L, et al. "Induction of Azoospermia in Normal Men With Combined Nal-Glu Gonadotropin-releasing Hormone Antagonist and Testosterone Enanthate." The Journal of Clinical Endocrinology and Metabolism, vol. 75, no. 2, 1992, pp. 476-83.
Tom L, Bhasin S, Salameh W, et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab. 1992;75(2):476-83.
Tom, L., Bhasin, S., Salameh, W., Steiner, B., Peterson, M., Sokol, R. Z., Rivier, J., Vale, W., & Swerdloff, R. S. (1992). Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. The Journal of Clinical Endocrinology and Metabolism, 75(2), 476-83.
Tom L, et al. Induction of Azoospermia in Normal Men With Combined Nal-Glu Gonadotropin-releasing Hormone Antagonist and Testosterone Enanthate. J Clin Endocrinol Metab. 1992;75(2):476-83. PubMed PMID: 1639948.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. AU - Tom,L, AU - Bhasin,S, AU - Salameh,W, AU - Steiner,B, AU - Peterson,M, AU - Sokol,R Z, AU - Rivier,J, AU - Vale,W, AU - Swerdloff,R S, PY - 1992/8/1/pubmed PY - 1992/8/1/medline PY - 1992/8/1/entrez KW - Americas KW - Androgens KW - Biology KW - California KW - Contraception KW - Contraception Research KW - Developed Countries KW - Endocrine System KW - Estradiol KW - Estrogens KW - Family Planning KW - Follicle Stimulating Hormone KW - Gonadotropins KW - Gonadotropins, Pituitary--men KW - Hormone Antagonists KW - Hormones KW - Luteinizing Hormone KW - Men KW - North America KW - Northern America KW - Physiology KW - Pituitary Hormone Releasing Hormones KW - Research Report KW - Testosterone KW - United States SP - 476 EP - 83 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 75 IS - 2 N2 - The effects of a combined GnRH antagonist and testosterone (T) replacement regimen on gonadotropins and spermatogenesis were examined to assess its potential as a male contraceptive regimen. The potent Nal-Glu GnRH antagonist ([Ac-D2-Nal1,D4-Cl-Phe2,D3-Pal3,Arg5, D4-p-methoxybenzoyl-2-amino butyric acid6,D-Ala10]GnRH) was administered daily (7.5 mg, sc) to eight normal men for 16 weeks. T enanthate was given im starting at week 2 and every 2 weeks thereafter through week 14 of the treatment phase. Serum LH, FSH, T, and estradiol concentrations were measured frequently during the 5-week control period, the 16-week treatment phase, and the 14-week recovery phase. Semen analyses were performed every week during the control phase and every 2 weeks during the treatment and recovery phases. Seven of eight subjects became azoospermic by 6-10 weeks of treatment; the eighth subject, who failed to achieve azoospermia, suppressed his sperm count to 7 million/mL by week 14 (from a mean baseline of 42 million/mL) before treatment was prematurely terminated because of localized swelling at each of his injection sites. Sperm counts returned to baseline 10-14 weeks after the end of Nal-Glu administration. Seven of the eight subjects showed suppression of LH to the limit of assay detection (less than 0.2 U/L), whereas the eighth subject showed incomplete suppression. Serum bioactive and immunoreactive LH concentrations showed concordant responses. Mean serum FSH concentrations were also markedly suppressed. Serum T and estradiol concentrations declined dramatically during the first 2 weeks of Nal-Glu GnRH treatment, but returned to the normal physiological range after T enanthate replacement was initiated. Libido and sexual potency were maintained. No systemic side-effects, other than erythema and induration at injection sites, were observed. These data demonstrate that combined GnRH antagonist plus T treatment can predictably and reversibly induce azoospermia in most men and has potential as a male contraceptive regimen. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/1639948/Induction_of_azoospermia_in_normal_men_with_combined_Nal_Glu_gonadotropin_releasing_hormone_antagonist_and_testosterone_enanthate_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.75.2.1639948 DB - PRIME DP - Unbound Medicine ER -